Status:
WITHDRAWN
Travacom Post Marketing Surveillance Study
Lead Sponsor:
Alcon Research
Conditions:
Open-angle Glaucoma
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this multi-center, open label, single arm, post-marketing surveillance study is to assess the safety of Travacom in patients with open-angle glaucoma or ocular hypertension who are insu...
Eligibility Criteria
Inclusion
- 18 years of age or older.
- Open-angle glaucoma or ocular hypertension insufficiently responsive to betablockers, prostaglandins, or other intraocular pressure-lowering (IOP) agents and when the use of Travacom is considered appropriate.
- Discontinued use of all other ocular hypotensive medications prior to receiving the study medication for the entire course of the study.
- Mean IOP not greater than 36 mmHG in either eye.
- Read, sign, and date (or legal representative) the Informed Consent prior to the start of any study-related procedures.
- Other protocol-defined inclusion criteria may apply.
Exclusion
- Women of childbearing potential (not postmenopausal for at least one year or not surgically sterile) who are currently pregnant, have a positive result on the urine pregnancy test at Screening, intend to become pregnant during the study period, are breastfeeding, or do not agree to use an adequate birth control method to prevent pregnancy throughout the study.
- Chronic, recurrent, or severe inflammatory eye disease, such as scleritis, uveitis, or herpes keratitis.
- History of clinically significant or progressive retinal disease.
- Best corrected visual acuity (BCVA) score worse than 20/80 Snellen.
- Bronchial asthma or related history that would preclude safe administration of a topical beta-blocker.
- Severe, unstable, or uncontrolled cardiovascular, hepatic, or renal disease or related history that would preclude safe administration of a topical beta-adrenergic blocking agent.
- History of spontaneous or current hypoglycemia or uncontrolled diabetes.
- Known medical allergy, hypersensitivity, or poor tolerance to any component of Travacom deemed clinically significant in the opinion of the Principal Investigator.
- Use of any additional topical or system ocular hypotensive medication during the study.
- Participation in any other investigational study within 30 days prior to Screening visit.
- Other protocol-defined exclusion criteria may apply.
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01510132
Start Date
January 1 2012
End Date
January 1 2012
Last Update
October 18 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.